Glycopyrrolate for Diabetic Mealtime Sweating: The 1997 Trial

The 1997 glycopyrrolate cream trial analysed 13 completers, including only one woman. Benefits specifically for women remain uncertain.¹

What the cream study tested

Fourteen people with diabetes were recruited. One withdrew after an eczema-like reaction to glycopyrrolate, leaving 13 completers. Each received 0.5% glycopyrrolate cream and placebo for two weeks each, separated by a one-week washout, in randomized order under double-blind conditions.¹

During a standardized food challenge, forehead sweat was collected on weighed dressings for 20 minutes, with limb measurements used as controls. Treatment reduced the sweat response by 82% relative to placebo. Diaries showed 51% fewer recorded sweating episodes. Neither figure means that 82% of patients were cured.¹

Most participants had both nerve and kidney complications of diabetes. The short crossover study did not establish long-term safety. Its findings concern this selected group and preparation.¹

Have the mealtime pattern assessed

NIDDK² describes how autonomic nerve damage can affect sweat glands, causing sweating during meals or at night. Other areas may stay dry, and temperature control can also be affected. These symptoms belong in a diabetes review.²

Assessment can include your symptom history, an examination, heart-rate and blood-pressure checks, and tests of nerve or sweat function. A familiar pattern does not establish the diagnosis on its own. Tell the clinician whether sweating begins while anticipating food, during eating or afterward, and whether it is limited to your face or scalp.²

Our meal-triggered sweating and diabetes article covers a later questionnaire study. That study concerns how often the symptom was reported; the cream trial concerns treatment.

Keep the product and application site specific

In the US, Qbrexza is a 2.4% glycopyrronium cloth for underarm use only. Its label specifies that it is not for other body areas. Moving that cloth onto the face would not reproduce the trial’s cream treatment.³

The label warns about eye exposure causing enlarged pupils or blurred vision, urinary retention and heat illness from reduced sweating. It also warns about combining it with other anticholinergic medicines. Those are reasons to have the prescriber review the exact product and your medicines, rather than treating every topical sweat medicine as interchangeable.³

If a clinician proposes a compounded facial cream, obtain written boundaries for where it can go, how to prevent eye transfer, what symptoms mean stop, and when to review the result. Explain any existing eye problems, difficulty emptying the bladder or trouble tolerating heat. Keep the cream’s instructions with its pharmacy label.

Keep your low-glucose plan available

If an episode includes shakiness, hunger, dizziness or confusion, check your blood glucose and follow your diabetes team’s hypoglycemia plan. Insulin and some other diabetes medicines can cause low glucose, and skipping or delaying meals can contribute. Do not assume every episode around food has the same cause.⁴

Severe low glucose can cause a seizure or loss of consciousness and requires immediate help. NIDDK⁴ advises planning with your team for glucagon and teaching people close to you how to use it and call 911. Your emergency plan should be settled before an episode in which you cannot treat yourself.⁴

Arms Up includes a Fresh Log for the body area, timing, wetness and interference with daily life. Bring those details to the diabetes appointment alongside your glucose records and medicines list. Ask what improvement you would compare at follow-up if treatment is prescribed.